Bilirubin, Total and Direct
The Bilirubin, Total and Direct test measures serum total bilirubin and its conjugated (direct) fraction to distinguish pre-hepatic, hepatic, and cholestatic causes of jaundice. Unconjugated hyperbilirubinaemia points to haemolysis or conjugation defects; conjugated hyperbilirubinaemia indicates cholestasis or hepatocellular disease impairing bile excretion.
3
Biomarkers
Blood (serum)
Sample
1–2 business days
Turnaround
No
Fasting
What is the Bilirubin test?
The Bilirubin, Total and Direct test measures serum total bilirubin and its conjugated (direct) fraction, with the unconjugated (indirect) component calculated by subtraction. It is ordered to evaluate jaundice, abnormal liver biochemistry, and suspected haemolysis, and to distinguish pre-hepatic, hepatic, and post-hepatic causes of hyperbilirubinaemia. Fractionation into direct and indirect components is the cornerstone of the jaundice work-up. Unconjugated hyperbilirubinaemia with normal liver enzymes points to haemolysis or Gilbert syndrome, while a raised direct fraction indicates cholestasis or hepatocellular disease and triggers imaging and further biochemical tests. Practitioners use this test not only diagnostically but also to monitor chronic liver disease, assess neonatal jaundice, and gauge synthetic and excretory function in the context of the broader liver panel.
What does the Bilirubin test measure?
Bilirubin is the end product of haem catabolism. Aged erythrocytes are broken down by reticuloendothelial macrophages, releasing haem, which is converted to unconjugated bilirubin. This lipophilic, albumin-bound form is transported to the liver, where hepatocytes conjugate it with glucuronic acid via UDP-glucuronosyltransferase to form water-soluble conjugated bilirubin. Conjugated bilirubin is then excreted into bile and reaches the intestinal lumen, where bacterial enzymes convert it to urobilinogen. Total bilirubin represents the sum of unconjugated and conjugated fractions in the circulation.
Total bilirubin is the primary screening marker for hyperbilirubinaemia and jaundice. An elevated total bilirubin prompts measurement of the direct (conjugated) fraction to distinguish hepatocellular and cholestatic causes from pre-hepatic haemolytic or genetic conjugation defects. It is a component of liver synthetic function assessment and forms part of prognostic models in chronic liver disease.
Direct bilirubin is the fraction that has been conjugated with glucuronic acid in hepatocytes, rendering it water-soluble and capable of biliary excretion. The laboratory assay measures conjugated bilirubin by direct diazo reaction without the need for alcohol. When hepatocyte excretion is impaired or bile ducts are obstructed, conjugated bilirubin regurgitates into the circulation and appears in urine, producing dark urine and cholestatic jaundice.
Direct bilirubin elevation indicates cholestasis or hepatocellular dysfunction affecting bile excretion. A direct fraction exceeding 20–30 per cent of total bilirubin is classified as conjugated hyperbilirubinaemia and narrows the differential to hepatobiliary causes — intrahepatic cholestasis, biliary obstruction, or inherited disorders such as Dubin-Johnson and Rotor syndromes.
Indirect bilirubin is the unconjugated, lipophilic fraction that circulates bound to albumin. It is derived from haem breakdown and must be taken up by hepatocytes and conjugated before excretion. Because it is not water-soluble, unconjugated bilirubin does not appear in urine but can cross lipid membranes, posing a risk of kernicterus in neonates when markedly elevated.
A predominance of indirect (unconjugated) bilirubin points to increased bilirubin production (haemolysis, ineffective erythropoiesis, resorption of large haematomas) or impaired conjugation (Gilbert syndrome, Crigler-Najjar syndrome). The indirect fraction is calculated rather than directly measured and is the primary diagnostic clue in pre-hepatic and some genetic causes of jaundice.
Why is the Bilirubin test ordered?
- Evaluation of clinical jaundice, scleral icterus, or dark urine in a patient with suspected liver or biliary disease
- Investigation of isolated hyperbilirubinaemia detected incidentally on a metabolic panel or during pre-operative screening
- Differential diagnosis of anaemia with suspected haemolysis, interpreted alongside haemoglobin, reticulocyte count, and haptoglobin
- Assessment of known or suspected Gilbert syndrome, Crigler-Najjar syndrome, or other inherited disorders of bilirubin metabolism
- Monitoring of chronic liver disease (viral hepatitis, cirrhosis, primary biliary cholangitis, primary sclerosing cholangitis), where rising bilirubin signals worsening synthetic function
- Work-up of cholestasis, in conjunction with alkaline phosphatase, GGT, ALT, AST, and imaging to localise obstruction
- Evaluation of drug-induced liver injury or cholestasis in patients on hepatotoxic or cholestatic medications
- Neonatal jaundice assessment, though paediatric-specific total and transcutaneous bilirubin protocols are usually applied in that setting
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
1–2 business days
Collection notes
Phlebotomy via LabCorp patient service centre. Protect the specimen from prolonged light exposure or process promptly to prevent photodegradation of bilirubin. Avoid haemolysis during collection, as it interferes with the assay.
Specimen requirements
Minimum 0.5 mL serum (gel separator acceptable). Separate from cells and protect from light; bilirubin is stable refrigerated for 24–48 hours if shielded from light. Reject grossly haemolysed specimens.
What can affect Bilirubin results?
Bilirubin is photosensitive and degrades under prolonged light exposure. Specimens should be protected from light or processed promptly; failure to do so can falsely lower results.
Haemolysed samples can spuriously elevate measured bilirubin owing to release of haemoglobin and interference with the diazo reaction; grossly haemolysed specimens should be rejected.
Fasting increases unconjugated bilirubin slightly, and prolonged fasting can unmask or exacerbate Gilbert syndrome. A non-fasting sample may therefore be more representative in some cases.
A common UGT1A1 promoter polymorphism reduces conjugation capacity, causing mild unconjugated hyperbilirubinaemia that fluctuates with illness, fasting, and stress. This benign condition is the most common cause of isolated raised bilirubin.
Rifampicin, some antiretrovirals, and other medications can compete for uptake or conjugation, transiently raising unconjugated bilirubin. Cholestatic drugs (certain antibiotics, anabolic steroids) raise the conjugated fraction.
Ascorbic acid can interfere with the diazo reaction in some assays, spuriously lowering measured bilirubin; clinical correlation is required if the result is unexpectedly low.
What do Bilirubin results mean?
Elevated
Elevated total bilirubin with a predominantly indirect (unconjugated) fraction suggests haemolysis, ineffective erythropoiesis, large haematoma resorption, or a conjugation defect (Gilbert, Crigler-Najjar). A predominantly direct (conjugated) fraction — typically more than 20–30 per cent of total — indicates cholestasis (intrahepatic or extrahepatic obstruction) or hepatocellular disease impairing excretion. Mixed elevations occur in severe hepatocellular injury and in cirrhosis. Clinical jaundice is usually visible when total bilirubin exceeds approximately 2.5–3.0 mg/dL.
Normal
A normal total and direct bilirubin effectively excludes significant hyperbilirubinaemia at the time of sampling. However, bilirubin can fluctuate, particularly in Gilbert syndrome, so a single normal result does not rule out intermittent jaundice. Always interpret in the context of liver enzymes, synthetic markers, and clinical presentation.
Reduced
Low bilirubin is rarely clinically significant and may be seen in conditions of low haem turnover. Spuriously low results can occur with photodegradation or assay interference from high-dose ascorbic acid.
Note: Fractionation is the key to diagnosis — unconjugated versus conjugated hyperbilirubinaemia points to different pathways. Protect specimens from light, reject haemolysed samples, and note that mild elevations are common and often benign (Gilbert syndrome). Total bilirubin is part of the Child-Pugh and MELD scores; serial measurement tracks prognosis in chronic liver disease. The terms 'direct' and 'conjugated' are used interchangeably, as are 'indirect' and 'unconjugated', but the laboratory measurement is only an approximation of true conjugated bilirubin.
Frequently asked questions
Total bilirubin is the sum of all bilirubin in the blood. Direct (conjugated) bilirubin has been processed by the liver and is water-soluble; indirect (unconjugated) bilirubin is the lipophilic fraction before hepatic conjugation. Indirect bilirubin is calculated by subtracting direct from total.
How to access the Bilirubin test
The Bilirubin reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Kwo PY, et al. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. (2017)
- European Association for the Study of the Liver. EASL clinical practice guidelines on the management of benign liver tumours. (2016)
- Roche SP, Kobos R. Jaundice in the adult patient. Am Fam Physician. (2004)
- Lidofsky SD. Jaundice. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 10th ed. Elsevier Saunders. (2016)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
gastrointestinal
ALT
The ALT test measures serum alanine aminotransferase, a cytosolic hepatocyte enzyme released during liver cell injury and the most liver-specific routine aminotransferase. It is the first-line marker of hepatocellular damage, interpreted with AST, ALP, GGT, and bilirubin and the AST:ALT ratio to classify liver injury, screen for steatotic liver disease, and monitor hepatotoxic therapy.
gastrointestinal
AST
The AST test measures serum aspartate aminotransferase, an enzyme present in liver, heart, skeletal muscle, and other tissues. It is a sensitive but non-specific marker of cellular injury, interpreted with ALT to calculate the AST:ALT ratio, which distinguishes steatotic (ratio <1) from alcohol-related (ratio >2) liver disease, and with CK and troponin to separate hepatic from muscle and cardiac…
gastrointestinal
ALP
The ALP test measures serum alkaline phosphatase, a group of tissue-specific isoenzymes expressed predominantly in liver (biliary epithelium) and bone (osteoblasts). It is the principal marker of cholestatic liver injury, interpreted with GGT to distinguish hepatobiliary from bone sources, and a key component of the liver panel used to classify hepatocellular versus cholestatic disease patterns.